A1C and cardiovascular outcomes in type 2 diabetes: A nested case-control study

Diabetes Care

Volumn 34, Issue 1, 2011, Pages 77-83

  Colayco, Danielle C ^a   Niu, Fang ^b   McCombs, Jeffrey S ^a   Cheetham, T Craig ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; NEUROLEPTIC AGENT; SULFONYLUREA; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETES CONTROL; FEMALE; GLYCEMIC CONTROL; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INTERNATIONAL CLASSIFICATION OF DISEASES; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; RISK ASSESSMENT; STROKE;

AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED;

EID: 79951699769     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-1318     Document Type: Article

References (22)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234 (Pubitemid 28350165)
2. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologica 2001;44(Suppl. 2):S14-S21 (Pubitemid 32844108)
3. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res and Clin Pract 1995;28:103-117
4. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837-853
5. Stratton IM, Adler AJ, Neil AW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412 (Pubitemid 30609442)
6. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
7. American Diabetes Association. Standards of Medical Care in Diabetes: 2010. Diabetes Care 2010;33(Suppl. 1):S11-S61
8. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, Hellman R, Jellinger PS, Jovanovic LG, Levy P, Mechanick JI, Zangeneh F. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocrine Practice 2007;13(Suppl. 1):3-68
9. Yang X, Kong APS, So WY, Ma RC, Ho CS, Lam CW, Chow CC, Cockram CS, Tong PC, Chan JC. Effects of chronic hyperglycaemia on incident stroke in Hong Kong Chinese patients with type 2 diabetes. Diabetes Metab Res Rev 2007;23:220-226 (Pubitemid 46437848)
10. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139
11. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24):2545-2559
12. Lachin JM. Sample size evaluation for a multiply matched case-control study using the score test from a conditional logistic (discrete Cox PH) regression model. Statistics in Medicine 2007;27:2509-2523 (Pubitemid 351982689)
13. Leslie RS, Gwadry-Sridhar F, Thiebaud P, Patel BV. Calculating medication compliance, adherence and persistence in administrative pharmacy claims databases. Pharmaceutical Programming 2008;1(1): 13-19
14. Currie CJ, Peters JR, Tynan A, Evans M, Heine R, Bracco O, Zagar T, Poole C. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;375(9713):481-489
15. Davies JS, Hinds NP, Millward Em, Mc-Dowell I, Scanlon MF. Hypokalaemia during insulin-induced hypoglycemia in hypopituitary adults with and without growth hormone deficiency. Clin Endocrinol (Oxf) 1998;49:217-220 (Pubitemid 28372651)
16. Lee SP, Yeoh L, Harris ND, Davies CM, Robinson RT, Leathard A, Newman C, Macdonald IA, Heller SR. Influence of autonomic neuropathy on QTc interval lengthening during hypoglycemia in type 1 diabetes. Diabetes 2004;53:1535-1542 (Pubitemid 38697666)
17. Choi SW, Benzie IF, Ma SW, Strain JJ, Hannigan BM. Acute hyperglycemia and oxidative stress: direct cause and effect? Free Radic Biol Med 2008;44:1217-1231
18. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158:1774-1782 (Pubitemid 33054769)
19. American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27(2):596-601
20. Davies HTO, Crombie IK, Tavakoli M. When can odds ratios mislead ? BMJ 1998;316:989-991
21. Riddle M, Bonds D, Duckworth W. New Analyses of ACCORD and VADT (late-breaking presentation). American Diabetes 69th Scientific Sessions, New Orleans, LA, 5-9 June 2009
22. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393 (Pubitemid 36159355)